|
|
|
51-200 employees
View all
|
|
Medical Device
|
|
30 Commerce Way, Woburn, Woburn, MA 01801, US
|
|
Adjacent to a lumbar discectomy, the Barricaid® device is designed to close large defects (>5mm) in the annulus, which often lead to disc reherniation and/or disc collapse. Barricaid is a permanent implant with two components - an occlusion component and an anchor. The occlusion component is comprised of a flexible polymer material designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position.
The Barricaid has been studied in a definitive – level 1B evidence - randomized superiority trial with over 550 patients enrolled (clinicaltrials.gov NCT01283438). The study focuses on patient at highest risk of reherniation and reoperation, enrolling only those patients with large defects (width >5 mm). The co-primary endpoints of reherniation and an 8-point composite of safety and effectiveness are evaluated at 2 years, with a parallel cost effectiveness analysis. Treated patients were found superior on both endpoints, with significantly lower rates of symptomatic recurrences (12% vs. 25%, p<0.001), index-level reoperations (9% vs. 16%, p=0.01), and device or procedure related serious adverse events (SAEs) (7% vs. 17%, p=0.001). Through two years, a total of 29 reoperations were performed in Barricaid subjects in comparison to 61 procedures in Controls. Study results are published in The Spine Journal, May 2018.
Barricaid is FDA-Approved
For full risk/benefit, see: www.barricaid.com/instructions-for-use
|
Intrinsic Therapeutics, Inc Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Intrinsic Therapeutics, Inc email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Intrinsic Therapeutics, Inc customer service number in your country click here to find.
Cary Hagan is the CEO of Intrinsic Therapeutics, Inc. To contact Cary Hagan email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.